Immune Modulation as a Treatment for Abdominal Aortic Aneurysms

S. Keisin Wang, Michael Murphy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In the United States, >200 000 new patients are diagnosed with abdominal aortic aneurysm (AAA) each year. Consequently, >40 000 highly morbid aortic reconstructions are performed each year to prevent aneurysm rupture, a catastrophic event associated with near-certain mortality. No pharmaceutical currently exists to slow aneurysm growth, but a 50% reduction in diameter growth per annum could halve the number of aortic reconstructions required. Therefore, successful use of cell therapy to modulate chronic inflammation hallmark to AAA to slow diameter expansion represents a potentially paradigmaltering treatment.

Original languageEnglish (US)
Pages (from-to)925-927
Number of pages3
JournalCirculation Research
Volume122
Issue number7
DOIs
StatePublished - Mar 30 2018

Fingerprint

Abdominal Aortic Aneurysm
Aneurysm
Growth
Cell- and Tissue-Based Therapy
Rupture
Inflammation
Mortality
Therapeutics
Pharmaceutical Preparations

Keywords

  • angiotensin II
  • aortic aneurysm, abdominal
  • doxycycline
  • matrix metalloproteinases
  • risk factors

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Immune Modulation as a Treatment for Abdominal Aortic Aneurysms. / Wang, S. Keisin; Murphy, Michael.

In: Circulation Research, Vol. 122, No. 7, 30.03.2018, p. 925-927.

Research output: Contribution to journalArticle

@article{a7305f471bb34942a6104ddd2a756cfb,
title = "Immune Modulation as a Treatment for Abdominal Aortic Aneurysms",
abstract = "In the United States, >200 000 new patients are diagnosed with abdominal aortic aneurysm (AAA) each year. Consequently, >40 000 highly morbid aortic reconstructions are performed each year to prevent aneurysm rupture, a catastrophic event associated with near-certain mortality. No pharmaceutical currently exists to slow aneurysm growth, but a 50{\%} reduction in diameter growth per annum could halve the number of aortic reconstructions required. Therefore, successful use of cell therapy to modulate chronic inflammation hallmark to AAA to slow diameter expansion represents a potentially paradigmaltering treatment.",
keywords = "angiotensin II, aortic aneurysm, abdominal, doxycycline, matrix metalloproteinases, risk factors",
author = "Wang, {S. Keisin} and Michael Murphy",
year = "2018",
month = "3",
day = "30",
doi = "10.1161/CIRCRESAHA.118.312870",
language = "English (US)",
volume = "122",
pages = "925--927",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Immune Modulation as a Treatment for Abdominal Aortic Aneurysms

AU - Wang, S. Keisin

AU - Murphy, Michael

PY - 2018/3/30

Y1 - 2018/3/30

N2 - In the United States, >200 000 new patients are diagnosed with abdominal aortic aneurysm (AAA) each year. Consequently, >40 000 highly morbid aortic reconstructions are performed each year to prevent aneurysm rupture, a catastrophic event associated with near-certain mortality. No pharmaceutical currently exists to slow aneurysm growth, but a 50% reduction in diameter growth per annum could halve the number of aortic reconstructions required. Therefore, successful use of cell therapy to modulate chronic inflammation hallmark to AAA to slow diameter expansion represents a potentially paradigmaltering treatment.

AB - In the United States, >200 000 new patients are diagnosed with abdominal aortic aneurysm (AAA) each year. Consequently, >40 000 highly morbid aortic reconstructions are performed each year to prevent aneurysm rupture, a catastrophic event associated with near-certain mortality. No pharmaceutical currently exists to slow aneurysm growth, but a 50% reduction in diameter growth per annum could halve the number of aortic reconstructions required. Therefore, successful use of cell therapy to modulate chronic inflammation hallmark to AAA to slow diameter expansion represents a potentially paradigmaltering treatment.

KW - angiotensin II

KW - aortic aneurysm, abdominal

KW - doxycycline

KW - matrix metalloproteinases

KW - risk factors

UR - http://www.scopus.com/inward/record.url?scp=85053888624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053888624&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.118.312870

DO - 10.1161/CIRCRESAHA.118.312870

M3 - Article

C2 - 29599276

AN - SCOPUS:85053888624

VL - 122

SP - 925

EP - 927

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 7

ER -